Lu J, Wang Z, Cao J, Chen Y, Dong Y
The benefit of healthy lifestyle in the era of new medications to treat obesity
In pre-clinical research, Semax rapidly elevates brain-derived neurotrophic factor (BDNF) and its signalling receptor TrkB in the hippocampus, modulates dopaminergic and serotonergic neurotransmitter systems, and demonstrates consistent neuroprotective effects in ischaemia models
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
Semaglutide Versus Dulaglutide Once Weekly in Patients with Type 2 Diabetes (SUSTAIN 7): A Randomised, Open-Label, Phase 3b Trial